We are a pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing a broad portfolio of projects under development of therapeutic and diagnostic technologies to tackle unmet medical needs. Our principal office in Asia provides easy access to prosperous medical research resources and some of the worldâs most talented specialists and clinicians. We have established strong relationships and collaborations with leading academic institutions to propel therapeutic innovations. To date, Aptorum has obtained 12 exclusively licensed technologies in the areas of neurology, infectious diseases, gastroenterology, oncology, surgical robotics and natural health. Source
No articles found.
Personalis, Inc. is a growing cancer genomics company transforming the development...
Personalis, Inc. is a growing cancer genomics c...
bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., h...
bluebird bio is pioneering gene therapy with pu...
MEI Pharma (Nasdaq: MEIP) is a San Diego-based late-stage pharmaceutical company f...
MEI Pharma (Nasdaq: MEIP) is a San Diego-based ...
Forty Seven is a clinical-stage immuno-oncology company focused on developing nove...
Forty Seven is a clinical-stage immuno-oncology...
Join the National Investor Network and get the latest information with your interests in mind.